Dipeptidyl Peptidase-4 Inhibitor

[...]it is also true that the same trials confirmed that the incidence of nonfatal myocardial infarction was significantly lower in the intensive glucose-lowering group compared with the standard therapy group (6,7,10). [...]the UKPDS 80 (United Kingdom Prospective Diabetes Study) demonstrated that...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 59; no. 3; pp. 277 - 279
Main Author Murohara, Toyoaki, MD, PhD
Format Journal Article
LanguageEnglish
Published New York Elsevier Limited 2012
Subjects
Apolipoproteins
Atherosclerosis
Cardiology
Cardiovascular
Cardiovascular disease
Diabetes
Drugs
Glucose
Heart attacks
Hyperglycemia
Internal Medicine
Mortality
Peptides
Rodents
Studies
atherosclerosis
dipeptidyl peptidase-4 inhibitors
endothelium
receptors
inflammation
glucagon-like peptide-1 receptor
Online AccessGet full text

Cover

More Information
Summary:[...]it is also true that the same trials confirmed that the incidence of nonfatal myocardial infarction was significantly lower in the intensive glucose-lowering group compared with the standard therapy group (6,7,10). [...]the UKPDS 80 (United Kingdom Prospective Diabetes Study) demonstrated that better control of blood glucose was associated with continued risk reduction for microvascular complications, myocardial infarction, and all-cause death during 10 years of post-trial follow-up, a phenomenon called the "legacy effect" (4). Diabetic states augment reactive oxygen species, inflammatory responses, endothelial dysfunction, and lipid deposition in the vascular wall and thereby promote atherosclerosis (13). [...]drugs that can not only control blood glucose levels but also inhibit cardiovascular complications are further desired.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2011.09.050